tiprankstipranks
Trending News
More News >
AnGes Inc (JP:4563)
:4563
Advertisement

AnGes (4563) AI Stock Analysis

Compare
0 Followers

Top Page

JP

AnGes

(OTC:4563)

Rating:38Underperform
Price Target:
¥54.00
▼(-11.48%Downside)
AnGes's overall stock score is heavily impacted by its poor financial performance and challenging valuation. Significant operating losses and negative cash flows drive a low financial performance score. Technical analysis also reflects bearish trends, further affecting the score. The lack of earnings call and corporate events data means the score is primarily influenced by the financial and technical components.

AnGes (4563) vs. iShares MSCI Japan ETF (EWJ)

AnGes Business Overview & Revenue Model

Company DescriptionAnGes, Inc. (4563) is a biotechnology company headquartered in Japan, specializing in the development and commercialization of gene-based medicines. The company's core focus is on the research and development of innovative therapies targeting genetic and rare diseases, cardiovascular diseases, and infectious diseases. AnGes is dedicated to advancing its proprietary gene therapy technologies and enhancing its product pipeline to address unmet medical needs globally.
How the Company Makes MoneyAnGes makes money primarily through the development and commercialization of its gene therapy products. The company's revenue streams are driven by product sales, licensing agreements, and collaborative partnerships with pharmaceutical companies and research institutions. AnGes engages in strategic partnerships to co-develop and out-license its innovative therapies, which allows it to generate upfront payments, milestone payments, and royalties. Additionally, the company may also receive funding and grants from governmental and non-governmental organizations to support its research and development efforts.

AnGes Financial Statement Overview

Summary
AnGes faces significant financial challenges, with deeply negative EBIT and net income margins. Despite revenue growth, substantial operating losses indicate potential structural or strategic issues. The balance sheet shows a low debt-to-equity ratio, but declining stockholders' equity and persistent negative cash flow raise concerns about sustainability and operational efficiency.
Income Statement
25
Negative
AnGes has faced significant challenges in maintaining profitability. The company's EBIT and Net Income margins are deeply negative, indicating considerable losses. While revenue has grown from previous periods, the growth is overshadowed by substantial operating losses. This points to potential structural or strategic challenges in its operations.
Balance Sheet
40
Negative
The balance sheet reflects a moderate financial structure with some areas of concern. The debt-to-equity ratio is low, which is a positive sign of limited leverage. However, the consistent decline in stockholders' equity over recent years and negative net income impact return on equity. Despite a negative net debt position, indicating more cash than debt, persistent losses raise concerns about long-term sustainability.
Cash Flow
30
Negative
Cash flow analysis reveals ongoing cash constraints, with persistent negative free cash flow. The operating cash flow is also negative, further emphasizing cash management challenges. The company has relied on financing activities to support cash flow needs, indicating a dependency on external funding.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue643.00M152.99M67.06M64.15M40.00M
Gross Profit247.00M18.00M-2.92B7.43M16.98M
EBITDA-5.74B-8.86B-13.41B-13.21B-4.19B
Net Income-28.13B-7.44B-14.71B-13.68B-4.21B
Balance Sheet
Total Assets4.67B28.89B38.82B45.46B38.35B
Cash, Cash Equivalents and Short-Term Investments1.71B4.16B11.04B17.90B11.54B
Total Debt272.45M362.68M1.16B0.000.00
Total Liabilities2.51B2.79B8.40B6.82B5.67B
Stockholders Equity2.16B26.10B30.43B38.63B32.68B
Cash Flow
Free Cash Flow-6.69B-8.84B-11.23B-11.46B-3.04B
Operating Cash Flow-6.61B-8.74B-11.21B-11.38B-2.96B
Investing Cash Flow-130.80M-356.65M-97.14M-154.87M-6.96B
Financing Cash Flow4.20B2.04B3.57B17.38B11.40B

AnGes Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price61.00
Price Trends
50DMA
64.56
Negative
100DMA
65.68
Negative
200DMA
59.41
Positive
Market Momentum
MACD
-1.49
Negative
RSI
46.02
Neutral
STOCH
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4563, the sentiment is Neutral. The current price of 61 is below the 20-day moving average (MA) of 61.30, below the 50-day MA of 64.56, and above the 200-day MA of 59.41, indicating a neutral trend. The MACD of -1.49 indicates Negative momentum. The RSI at 46.02 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4563.

AnGes Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
58
Neutral
¥27.86B
-2.34%-278.32%
52
Neutral
$7.47B-0.04-63.86%2.34%16.17%0.25%
51
Neutral
¥63.86B
374.19%35.53%
47
Neutral
¥18.58B
-100.00%-1079.89%
45
Neutral
¥16.40B
-4.04%-0.88%
38
Underperform
$21.18B-193.61%179.79%-204.13%
32
Underperform
¥19.97B
-9.65%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4563
AnGes
61.00
14.00
29.79%
JP:4575
CanBas Co., Ltd.
1,022.00
349.00
51.86%
JP:4593
Healios KK
694.00
511.00
279.23%
JP:4599
StemRIM Inc.
307.00
-155.00
-33.55%
JP:7774
Japan Tissue Engineering Co., Ltd.
666.00
-49.00
-6.85%
JP:7776
CellSeed Inc.
472.00
-315.00
-40.03%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 08, 2025